I'm not so sure Art. The new CEO has been much lauded and this act of cutting short a clinical trial will be read as "making the hard decisions for the future good"...which it probably is. One poster called for "heads to roll"...well the heads that should roll, already have rolled, IMO. Rolled off into the sunset with about 30 million free shares each. Not bad. So no new heads to roll...except maybe someone in the "comms dept"...we all know who that is.
I'm starting to think that someone in ADO, a long time ago, must have been out in their yacht and shot some pesky albatross that was hanging around. Then, on the way home they ran over 13 black cats that dashed onto the road from the left side. On their way to their house from the garage, they walked under a ladder, then tripped over a mirror and broke it. Somehow all this bad luck was transferred to ADO.
So now there's a "new priority" to fast-track development of the multiplex test and some others. That's OK, but they needn't think they're the only ones. I'm sure I've seen Covid/Flu A/Flu B tests already on the market? (Don't take that as fact; I need to check.)
So, once again the long-suffering SHs get to wait while buckets of free options are doled out to employees for "performance" (jeez; I thought that's what their salary was for!)
Once again, the mirage of Eugeni success drifts further into the distance.
ADO Price at posting:
5.7¢ Sentiment: Hold Disclosure: Held
